Literature DB >> 26071130

[Endobronchial ultrasound in the diagnosis of malignant pleural mesothelioma].

J Guinde1, S Laroumagne1, E Kaspi2, S Martinez1, R Tazi-Mezalek1, P Astoul3, H Dutau4.   

Abstract

The diagnosis of malignant pleural mesothelioma relies mostly on the pathological examination of pleural samples, validated by a panel of experts and generally obtained during medical or surgical thoracoscopy performed for the management of an exudative pleural effusion. In the absence of pleural effusion (dry-type mesothelioma), the diagnostic approach depends on the features of the lesions (pleural thickness, nodules and/or masses) and their pleural location. Ultrasound and CT-guided needle aspiration represent recognized alternative diagnostic techniques in these situations. We present the case of a patient, presenting a dry-type mesothelioma, whose diagnosis was obtained by endobronchial ultrasound (EBUS)-guided needle aspiration of a pleural mediastinal mass and confirmed by a CT-guided needle aspiration of another pleural mass in close contact with the chest wall. The samples have been compared and show quantitative and qualitative similarities. EBUS represents a minimally invasive alternative diagnostic technique for dry-type mesothelioma, showing thickness of the mediastinal pleura in contact with a central airway or when thoracoscopy, which remains the "gold standard" diagnostic approach, is not feasible.
Copyright © 2015 SPLF. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Bronchoscopie; Bronchoscopy; Endobronchial ultrasound bronchoscopy; Mésothéliome pleural; Pleura; Pleural mesothelioma; Plèvre; Échoendoscopie

Mesh:

Year:  2015        PMID: 26071130     DOI: 10.1016/j.rmr.2014.12.009

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN: 0761-8425            Impact factor:   0.622


  1 in total

1.  Pleural mesothelioma: When echo-endoscopy (EUS-B-FNA) leads to diagnosis in a minimally invasive way.

Authors:  Roberto Piro; Matteo Fontana; Francesco Livrieri; Francesco Menzella; Eleonora Casalini; Sofia Taddei; Federica De Giorgi; Nicola Facciolongo
Journal:  Thorac Cancer       Date:  2021-02-03       Impact factor: 3.500

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.